BioLineRx Ltd (BLRX)

[midastouch017]

BioLineRx Ltd. (NASDAQ:BLRX) Receives $3.62 Consensus Target Price from Analysts

August 4th, 2017 - By Jessica Moore - 0 comments

BioLineRx logoBioLineRx Ltd. (NASDAQ:BLRX) has received an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $2.85.

A number of research firms have commented on BLRX. Roth Capital began coverage on shares of BioLineRx in a research report on Thursday. They set a “buy” rating and a $3.00 target price on the stock. Oppenheimer Holdings, Inc. began coverage on shares of BioLineRx in a research report on Friday. They set an “outperform” rating and a $3.00 target price on the stock. Zacks Investment Research raised shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Wednesday, July 26th. ValuEngine raised shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Maxim Group set a $3.00 target price on shares of BioLineRx and gave the company a “buy” rating in a research report on Thursday, May 25th.